Hairy Cell Leukemia Hcl Market

DelveInsight’s “Hairy Cell Leukemia Market Insights, Epidemiology, and Market Forecast – 2030” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the market trends of Hairy Cell Leukemia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 


The Hairy Cell Leukemia (HCL) market report provides analysis regarding current treatment practices, emerging drug-like Moxetumumab (Innate Pharma) and potential therapies, market share of the individual therapies, historical, current, and forecasted Hairy Cell Leukemia market size from 2017 to 2030, segmented by seven major markets.


The report also covers current Hairy Cell Leukemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Hairy Cell Leukemia - Disease Understanding and Treatment Algorithm

Hairy Cell Leukemia Overview

The World Health Organization (WHO) (2018) categorizes hairy cell leukemia as a mature B-cell neoplasm. It is called hairy cell leukemia because hair-like projections can be seen on the surface of the cancer cells when they are viewed under a microscope.


HCL is a rare B-cell lymphoproliferative disease, accounting for about 2–3% of all leukemias in adults in the western world. The male/female ratio is 4:1, and the median age of diagnosis is 52 years. It is a cancer of blood and bone marrow in which the bone marrow makes too many lymphocytes. This rare type of leukemia gets worse slowly or does not get worse at all.


Diagnosis of HCL is suspected on physical examination, marrow and splenic biopsy, and computed tomography (CT) scan, as well as laboratory tests that show raised white blood cell count (>10 × 109/L). The differential diagnosis includes splenic lymphoma with villous lymphocytes (SLVL), splenic diffuse red pulp lymphoma (SRPL), HCL-C, mantle-cell lymphoma, B-cell prolymphocytic leukemia (B-PLL), and HCL-Jv.


Hairy Cell Leukemia Treatment

This chapter covers the details of conventional and current medical therapies available in the Hairy Cell Leukemia market to treat the condition. It also provides the country-wise Hairy Cell Leukemia treatment guidelines across the United States, Europe, and Japan.


DelveInsight’s Hairy Cell Leukemia market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Hairy Cell Leukemia treatment algorithms and treatment guidelines in the US, Europe, and Japan.


The treatment options for Hairy Cell Leukemia may depend on the following:


  • The number of hairy (leukemia) cells and healthy blood cells in the blood and bone marrow
  • Whether the spleen is swollen
  • Whether there are signs or symptoms of leukemia, such as infection
  • Whether leukemia has recurred after previous treatment


The prognosis depends on the following:


  • Whether the hairy cell leukemia does not grow or grows so slowly, it does not need treatment
  • Whether the hairy cell leukemia responds to treatment

Purine analogues cladribine and pentostatin are first-line agents in the treatment of HCL

Hairy Cell Leukemia Epidemiology

The Hairy Cell Leukemia epidemiology chapters provide insights about historical and current adult-onset Still’s disease patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Hairy Cell Leukemia epidemiology is segmented by total diagnosed incident cases, gender-specific cases, age-specific cases, and cases of HCL by symptoms. The report includes a thorough analysis of all segmentations.


According to DelveInsight’s estimate, the total diagnosed incident cases of hairy cell leukemia in the 7MM countries was 2,399 in 2017. As per the estimates, the United States had the highest diagnosed incident population of hairy cell leukemia with 1,142 cases in 2017.

Hairy Cell Leukemia Drug Chapters

The drug chapter segment of the Hairy Cell Leukemia report encloses the detailed analysis of the Hairy Cell Leukemia pipeline drug. It also helps understand the Hairy Cell Leukemia clinical trial details, expressive pharmacological action, the included drug’s agreements, and the latest news and press releases.


The treatment HCL is aimed to reduce the number of abnormal cells to as low as possible. It is generally accepted that standard treatment will not cure HCL, but it does offer a very high chance of a normal lifespan with a good quality of life. Therapies used in the early 1980s including splenectomy and interferon, were replaced with purine analogs (PA) pentostatin and cladribine before 1990. Cladribine and pentostatin remain the accepted first-line regimens. Apart from these, many drugs are still under trial or need more proper studies to prove efficacy. Thus, any significant development in this direction is expected to create a tectonic impact on the existing market scenario during our forecast period.

Hairy Cell Leukemia Market Outlook

The Hairy Cell Leukemia market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounted for the largest hairy cell leukemia market size, with USD 36.9 million in 2017.

Hairy Cell Leukemia Drugs Uptake

This section focuses on the uptake of the potential drugs in the Hairy Cell Leukemia market expected to get launched in the market during the study period 2017–2030. The analysis covers the Hairy Cell Leukemia market uptake by drugs, patient uptake by therapies, and drug sale.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


The dynamics of the Hairy Cell Leukemia market is anticipated to experience a positive shift in the coming years due to the expected launch of emerging therapies.

Hairy Cell Leukemia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Hairy Cell Leukemia key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers Hairy Cell Leukemia collaborations, acquisition and merger, licensing, patent details, and other information for Hairy Cell Leukemia emerging therapies.

Reimbursement Scenario in Hairy Cell Leukemia

Proactively approaching reimbursement can positively impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Hairy Cell Leukemia domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Hairy Cell Leukemia Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights

  • In the coming years, the Hairy Cell Leukemia market scenario is expected to alter across the 7MM due to the launch of a few therapies covering the drawbacks of the standard of care.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hairy Cell Leukemia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Hairy Cell Leukemia Pipeline Analysis
  • Hairy Cell Leukemia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hairy Cell Leukemia Report Key Strengths

  • 11-years Forecast
  • 7MM Coverage
  • Hairy Cell Leukemia Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Hairy Cell Leukemia Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Hairy Cell Leukemia market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the Hairy Cell Leukemia total market size and market size by therapies across the 7MM during the forecast period (2017–2030)?
  • What are the key findings of the market across 7MM, and which country will have the largest Hairy Cell Leukemia market size during the forecast period (2017–2030)?
  • At what CAGR, Hairy Cell Leukemia market is expected to grow in 7MM during the forecast period (2017–2030)?
  • What would be the Hairy Cell Leukemia market outlook across the 7MM during the forecast period (2017–2030)?
  • What would be the Hairy Cell Leukemia market growth until 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risks, burdens, and unmet needs of Hairy Cell Leukemia?
  • What is the historical Hairy Cell Leukemia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Hairy Cell Leukemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population of Hairy Cell Leukemia?
  • Out of all 7MM countries, which country would have the highest diagnosed incident population of Hairy Cell Leukemia during the forecast period (2017–2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for Hairy Cell Leukemia treatment, along with the approved therapy?
  • What are the current treatment guidelines for treating Hairy Cell Leukemia in the USA, Europe, and Japan?
  • What is the Hairy Cell Leukemia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Hairy Cell Leukemia?
  • How many therapies are developed by each company for Hairy Cell Leukemia treatment?
  • How many are emerging therapies in mid-stage and late-stage of development for Hairy Cell Leukemia treatment?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hairy Cell Leukemia therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hairy Cell Leukemia and their status?
  • What are the key designations that have been granted for the emerging therapies for Hairy Cell Leukemia?
  • What are the global historical and forecasted market of Hairy Cell Leukemia?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Hairy Cell Leukemia market
  • To understand the future market competition in the Hairy Cell Leukemia market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hairy Cell Leukemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Hairy Cell Leukemia market
  • To understand the future market competition in the Hairy Cell Leukemia market


Which geography accounted for the largest Hairy Cell Leukemia market size?

The United States accounted for the largest Hairy Cell Leukemia market size.


What is the forecasted Hairy Cell Leukemia market size in 2030?

DelveInsight estimates an increase in Hairy Cell Leukemia Market Size during the study period, 2017–2030


What is the present Hairy Cell Leukemia market drivers?

The novel emerging options and current advancements in the treatment are likely to drive the HCL market.


What is Hairy Cell Leukemia market barriers?

Key barriers to drug development include failure to precise diagnosis and lack of awareness about the disease.


How many companies are developing drugs for Hairy Cell Leukemia?

Two companies are working robustly in providing effective treatment to individuals suffering from HCL.


Which are the leading companies in the Hairy Cell Leukemia market?

Roche and Innate Pharma.


How is epidemiology segmented for Hairy Cell Leukemia?

It is segmented into the total diagnosed incidence cases, gender-specific cases, age-specific cases, and cases of HCL by symptoms. 

1. Key Insights

2. Executive Summary of HCL

3. Hairy Cell Leukemia Market Overview at a Glance

3.1. Market Share (%) Distribution of Hairy Cell Leukemia in 2017

3.2. Market Share (%) Distribution of Hairy Cell Leukemia in 2030

4. Disease Background and Overview

4.1. Introduction

4.2. Symptoms

4.3. Risk Factor

4.4. Staging and Risk Stratification

4.5. Genetics

4.6. Morphologic and Immunophenotypic Features

4.7. Biology of HCL

4.8. Pathogenesis

4.9. Diagnosis

4.9.1. Differential Diagnosis

4.10. Diagnostic Guidelines

4.10.1. NCCN Clinical Practice Guidelines in Oncology - Hairy Cell Leukemia, Version 2.2018

4.10.2. European Society for Medical Oncology (ESMO): Clinical Practice Guidelines - Hairy Cell Leukemia

4.10.3. Consensus guidelines for the diagnosis Classic Hairy Cell Leukemia

5. Epidemiology and Patient Population

5.1. Key Findings

6. 7MM Epidemiology

6.1. Assumptions and rationale

6.2. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in 7MM

6.3. The United States

6.3.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in the United States

6.3.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the United States

6.3.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in the United States

6.3.4. Gender-Specific cases of Hairy Cell Leukemia (HCL) in the United States

6.4. EU5 Countries

6.4.1. Germany

6.4.1.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Germany

6.4.1.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Germany

6.4.1.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in Germany

6.4.1.4. Gender-specific cases of Hairy Cell Leukemia (HCL) in Germany

6.4.2. France

6.4.2.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in France

6.4.2.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in France

6.4.2.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in France

6.4.2.1. Gender-specific cases of Hairy Cell Leukemia (HCL) in France

6.4.3. Italy

6.4.3.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Italy

6.4.3.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Italy

6.4.3.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in Italy

6.4.3.4. Gender-specific cases of Hairy Cell Leukemia (HCL) in Italy

6.4.4. Spain

6.4.4.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Spain

6.4.4.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Spain

6.4.4.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in Spain

6.4.4.4. Gender-specific cases of Hairy Cell Leukemia (HCL) in Spain

6.4.5. United Kingdom

6.4.5.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in the United Kingdom

6.4.5.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the United Kingdom

6.4.5.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in the United Kingdom

6.4.5.4. Gender-specific cases of Hairy Cell Leukemia (HCL) in the United Kingdom

6.4.6. Japan

6.4.6.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Japan

6.4.6.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Japan

6.4.6.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in Japan

6.4.6.4. Gender-specific cases of Hairy Cell Leukemia (HCL) in Japan

7. Treatment and Management

7.1. ESMO (European Society for Medical Oncology) Clinical Practice Guidelines for Treatment

7.2. Consensus Guidelines for the management of patients with classic Hairy Cell Leukemia

7.3. NCCN Clinical Practice Guidelines Hairy Cell Leukemia, Version 1.2021

7.3.1. Treatment Options

7.3.2. Treatment Guidelines

8. Unmet Needs

9. Organizations contributing toward HCL

10. Case studies

10.1. A Case Report of Hairy Cell Leukemia Presenting Concomitantly with Sweet Syndrome

10.2. Skin Metastasis in Patient with Hairy Cell Leukemia: Case Report

10.3. Tuberculous Meningoencephalitis in a Patient with Hairy Cell Leukemia in Complete Remission

10.4. A Case Report of CD27-positive hairy cell leukemia-Japanese variant

11. KOL Views

12. Patient Journey

13. Marketed Therapies

13.1. Leustatin: Janssen

13.1.1. Drug Description

13.1.2. Other Developmental Activities

13.1.3. Safety and Efficacy

13.2. Nipent: Pfizer

13.2.1. Product Description

13.2.2. Other Developmental Activities

13.2.3. Safety and Efficacy

13.3. Intron A: Merck

13.3.1. Product Description

13.3.2. Other Development Activities

13.3.3. Safety and Efficacy

13.4. Roferon-A: Roche

13.4.1. Product Description

13.4.2. Other Development Activities

13.4.3. Safety and Efficacy

14. Emerging Therapies

14.1. Key cross competition – Emerging Therapies

14.2. Lumoxiti: Innate Pharma/AstraZeneca

14.2.1. Drug Description

14.2.2. Other Developmental Activities

14.2.3. Clinical Development

14.2.3.1. Clinical Trial Description

14.3. Obinutuzumab: Roche

14.3.1. Product Description

14.3.2. Clinical Development

14.3.2.1. Clinical Trials Information

14.3.3. Safety and Efficacy

15. Other Promising Therapies

15.1. Ibrutinib: Johnson and Johnson/Pharmacyclics

15.1.1. Product Description

15.1.2. Other Development Activities

15.1.3. Clinical Development

15.1.3.1. Clinical Trials Information

15.1.4. Safety and Efficacy

15.2. Vemurafenib: Roche

15.2.1. Product Description

15.2.2. Other Development Activities

15.2.3. Clinical Development

15.2.3.1. Clinical Trials Information

15.2.4. Safety and Efficacy

16. Hairy Cell Leukemia (HCL): Seven Major Market Analysis

16.1. Key Findings

16.2. Market Size of Hairy Cell Leukemia (HCL) in 7MM

17. Seven Major Market Outlook

17.1. The United States Market Size

17.1.1. Total Market Size of Hairy Cell Leukemia (HCL) in the United States

17.1.2. Total Market Size of Hairy Cell Leukemia (HCL) by Therapies in the United States

17.2. Germany

17.2.1. The total market size of Hairy Cell Leukemia (HCL) in Germany

17.2.2. Market size of Hairy Cell Leukemia (HCL) by Therapies in Germany

17.3. France

17.3.1. The total market size of Hairy Cell Leukemia (HCL) in France

17.3.2. Market size of Hairy Cell Leukemia (HCL) by Therapies in France

17.4. Italy

17.4.1. Market size of Hairy Cell Leukemia (HCL) by Therapies in Italy

17.4.2. The total market size of Hairy Cell Leukemia (HCL) in Italy

17.5. Spain

17.5.1. Total Market Size of Hairy Cell Leukemia (HCL) in Spain

17.5.2. Market size of Hairy Cell Leukemia (HCL) by Therapies in Spain

17.6. United Kingdom

17.6.1. The total market size of Hairy Cell Leukemia (HCL) in the United Kingdom

17.6.2. Market size of Hairy Cell Leukemia (HCL) by Therapies in the UK

17.7. Japan

17.7.1. The total market size of Hairy Cell Leukemia (HCL) in Japan

17.7.2. Market size of Hairy Cell Leukemia (HCL) by Therapies in Japan

18. Market Drivers

19. Market Barriers

20. SWOT Analysis for HCL

21. Reimbursement

22. Appendix

22.1. Report Methodology

22.2. References

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Table

Table 1: Summary of Hairy Cell Leukemia Market, Epidemiology, and Key Events (2017–2030)

Table 2: Genomic alterations in hairy cell leukemia (HCL), hairy cell leukemia‐variant (HCL‐V), splenic diffuse red pulp lymphoma (SDRPL) and splenic marginal zone lymphoma (SMZL)

Table 3: NCCN Categories of Evidence and Consensus

Table 4: Diagnosis and workup for HCL by NCCN

Table 5: Diagnostic workup of classical HCL

Table 6: Diagnostic criteria for HCL and HCL-V

Table 7: Initial workup for a patient suspected of hairy cell leukemia

Table 8: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in 7MM (2017–2030)

Table 9: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in the United States (2017–2030)

Table 10: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the US (2017–2030)

Table 11: Age-specific Diagnosed Incident of Hairy Cell Leukemia in the US (2017–2030)

Table 12: Gender-specific cases of Hairy Cell Leukemia (HCL) in the US (2017–2030)

Table 13: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Germany (2017–2030)

Table 14: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Germany (2017–2030)

Table 15: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Germany (2017–2030)

Table 16: Gender-specific cases of Hairy Cell Leukemia (HCL) in Germany (2017–2030)

Table 17: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in France (2017–2030)

Table 18: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in France (2017–2030)

Table 19: Age-specific Diagnosed Incident of Hairy Cell Leukemia in France (2017–2030)

Table 20: Gender-specific cases of Hairy Cell Leukemia (HCL) in France (2017–2030)

Table 21: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Italy (2017–2030)

Table 22: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Italy (2017–2030)

Table 23: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Italy (2017–2030)

Table 24: Gender-specific cases of Hairy Cell Leukemia (HCL) in Italy (2017–2030)

Table 25: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Spain (2017–2030)

Table 26: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the US (2017–2030)

Table 27: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Spain (2017–2030)

Table 28: Gender-specific cases of Hairy Cell Leukemia (HCL) in Spain (2017–2030)

Table 29: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in the United Kingdom (2017–2030)

Table 30: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the UK (2017–2030)

Table 31: Age-specific Diagnosed Incident of Hairy Cell Leukemia in the UK (2017–2030)

Table 32: Gender-specific cases of Hairy Cell Leukemia (HCL) in the UK (2017–2030)

Table 33: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Japan (2017–2030)

Table 34: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the UK (2017–2030)

Table 35: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Japan (2017–2030)

Table 36: Gender-specific cases of Hairy Cell Leukemia (HCL) in Japan (2017–2030)

Table 37: Definition of response categories

Table 38: Initial workup for a patient suspected of hairy cell leukemia

Table 39: Implications for Recommendations

Table 40: Assessment of response in HCL

Table 41: Assessment of response in HCL

Table 42: Supportive Care

Table 43: Key cross competition - Emerging Therapies

Table 44: Lumoxiti, Clinical Trial Description, 2020

Table 45: obinutuzumab, Clinical Trial Description, 2020

Table 46: Ibrutinib, Clinical Trial Description, 2020

Table 47: Vemurafenib, Clinical Trial Description, 2020

Table 48: Market Size of Hairy Cell Leukemia (HCL) in 7MM in USD Million (2017–2030)

Table 49: The US Market Size of Hairy Cell Leukemia (HCL) in USD Million (2017–2030)

Table 50: US Market Size of Hairy Cell Leukemia (HCL) in USD Million (2017–2030)

Table 51: Market Size of Hairy Cell Leukemia (HCL) in Germany, USD Millions (2017–2030)

Table 52: Germany Market Size of Hairy Cell Leukemia (HCL) by Therapies in USD Million (2017–2030)

Table 53: Market Size of Hairy Cell Leukemia (HCL) associated in France, USD Millions (2017–2030)

Table 54: France Market Size of Hairy Cell Leukemia (HCL) by Therapies in USD Million (2017–2030)

Table 55: Italy Market Size of Hairy Cell Leukemia (HCL) by Therapies in USD Million (2017–2030)

Table 56: Market Size of Hairy Cell Leukemia (HCL) in Italy, USD Millions (2017–2030)

Table 57: Market Size of Hairy Cell Leukemia (HCL) in Spain, USD Millions (2017–2030)

Table 58: Spain Market Size of Hairy Cell Leukemia (HCL) by Therapies in USD Million (2017–2030)

Table 59: Market Size of Hairy Cell Leukemia (HCL) in the UK, USD Millions (2017–2030)

Table 60: UK Market Size of Hairy Cell Leukemia (HCL) by Therapies in USD Million (2017–2030)

Table 61: Market Size of Hairy Cell Leukemia (HCL) in Japan, USD Millions (2017–2030)

Table 62: Japan Market Size of Hairy Cell Leukemia (HCL) by Therapies in USD Million (2017–2030)

List of Figures

Figure 1: RAF-MEK-ERK signaling pathway in hairy cell leukemia

Figure 2: B-cell development in peripheral lymphoid organs: the germinal center reaction

Figure 3: Signaling pathways involved in hairy-cell leukemia (HCL) growth

Figure 4: Hairy-cell leukemia (HCL) homing and dissemination properties

Figure 5: Bone-marrow fibrosis in hairy-cell leukemia (HCL)

Figure 6: ‘Hairy’ morphology: molecular mediators and their relationship with hairy-cell survival

Figure 7:  Histologic image of a hairy cell

Figure 8: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in 7MM (2017–2030)

Figure 9: Total Diagnosed Incident Cases of HCL in the United States (2017–2030)

Figure 10: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the US (2017–2030)

Figure 11: Age-specific Diagnosed Incident of Hairy Cell Leukemia in the US (2017–2030)

Figure 12: Gender-Specific cases of Hairy Cell Leukemia (HCL) in the US (2017–2030)

Figure 13: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Germany (2017–2030)

Figure 14: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Germany (2017–2030)

Figure 15: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Germany (2017–2030)

Figure 16: Gender-specific cases of Hairy Cell Leukemia (HCL) in Germany (2017–2030)

Figure 17: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in France (2017–2030)

Figure 18: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in France (2017–2030)

Figure 19: Age-specific Diagnosed Incident of Hairy Cell Leukemia in France (2017–2030)

Figure 20: Gender-specific cases of Hairy Cell Leukemia (HCL) in France (2017–2030)

Figure 21: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Italy (2017–2030)

Figure 22: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Italy (2017–2030)

Figure 23: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Italy (2017–2030)

Figure 24: Gender-specific cases of Hairy Cell Leukemia (HCL) in Italy (2017–2030)

Figure 25: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Spain (2017–2030)

Figure 26: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Spain (2017–2030)

Figure 27: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Spain (2017–2030)

Figure 28: Gender-specific cases of Hairy Cell Leukemia (HCL) in Spain (2017–2030)

Figure 29: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in the UK (2017–2030)

Figure 30: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the UK (2017–2030)

Figure 31: Age-specific Diagnosed Incident of Hairy Cell Leukemia in the UK (2017–2030)

Figure 32: Gender-specific cases of Hairy Cell Leukemia (HCL) in the UK (2017–2030)

Figure 33: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Japan (2017–2030)

Figure 34: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Japan (2017–2030)

Figure 35: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Japan (2017–2030)

Figure 36: Gender-specific cases of Hairy Cell Leukemia (HCL) in Japan (2017–2030)

Figure 37: Treatment Algorithm

Figure 38: Treatment algorithm for relapsed and refractory classical HCL according to ESMO guidelines

Figure 39: Treatment algorithm according to ESMO guidelines

Figure 40: Treatment algorithm according to ESMO guidelines

Figure 41: NCCN Treatment Guidelines

Figure 42: Unmet Needs

Figure 43: Market Size of Hairy Cell Leukemia (HCL) in USD Million (2017–2030)

Figure 44: Market Size of Hairy Cell Leukemia (HCL) in the US, USD Millions (2017–2030)

Figure 45: Market Size of Hairy Cell Leukemia (HCL) in the US by therapies, USD Millions (2017–2030)

Figure 46: Market Size of Hairy Cell Leukemia (HCL) in Germany, USD Millions (2017–2030)

Figure 47: Market Size of Hairy Cell Leukemia (HCL) in Germany by therapies, USD Millions (2017–2030)

Figure 48: Market Size of Hairy Cell Leukemia (HCL) in France, USD Millions (2017–2030)

Figure 49: Market Size of Hairy Cell Leukemia (HCL) in France by therapies, USD Millions (2017–2030)

Figure 50: Market Size of Hairy Cell Leukemia (HCL) in Italy by therapies, USD Millions (2017–2030)

Figure 51: Market Size of Hairy Cell Leukemia (HCL) in Italy, USD Millions (2017–2030)

Figure 52: Market Size of Hairy Cell Leukemia (HCL) in Spain, USD Millions (2017–2030)

Figure 53: Market Size of Hairy Cell Leukemia (HCL) in Spain by therapies, USD Millions (2017–2030)

Figure 54: Market Size of Hairy Cell Leukemia (HCL) in the UK, USD Millions (2017–2030)

Figure 55: Market Size of Hairy Cell Leukemia (HCL) in the UK by therapies, USD Millions (2017–2030)

Figure 56: Market Size of Hairy Cell Leukemia (HCL) in Japan, USD Millions (2017–2030)

Figure 57: Market Size of Hairy Cell Leukemia (HCL) in Japan by therapies, USD Millions (2017–2030)

Figure 58: Market Drivers

Figure 59: Market Barriers

Roche

Innate Pharma

  • Tags:
  • Hairy Cell Leukemia (HCL) market
  • Hairy Cell Leukemia (HCL) market r...
  • Hairy Cell Leukemia (HCL) market i...
  • Hairy Cell Leukemia (HCL) market t...
  • Hairy Cell Leukemia (HCL) market f...
  • Hairy Cell Leukemia (HCL) market s...
  • Hairy Cell Leukemia (HCL) pipeline...
  • Hairy Cell Leukemia (HCL) treatmen...
  • Hairy Cell Leukemia (HCL) drugs
  • Hairy Cell Leukemia (HCL) sales fo...
  • Hairy Cell Leukemia (HCL) market s...
  • Hairy Cell Leukemia (HCL) disease
  • Hairy Cell Leukemia (HCL) epidemio...
  • Hairy Cell Leukemia (HCL)

Forward to Friend

Need A Quote